Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

Abstract Background Several novel androgen receptor pathway targeted agents have recently entered on to therapeutic landscape for metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the effect of these novel androgen receptor pathway targeted agents in impr...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2016-07, Vol.61, p.111-121
Main Authors: Roviello, Giandomenico, Sigala, Sandra, Sandhu, Shahneen, Bonetta, Alberto, Cappelletti, Maria Rosa, Zanotti, Laura, Bottini, Alberto, Sternberg, Cora N, Fox, Stephen B, Generali, Daniele
Format: Article
Language:English
Subjects:
Abiraterone acetate
Androgen Receptor Antagonists - therapeutic use
Antineoplastic Agents - therapeutic use
Disease-Free Survival
Enzalutamide
Hematology, Oncology and Palliative Medicine
Humans
Male
Molecular Targeted Therapy - methods
Orteronel
Proportional Hazards Models
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Randomized Controlled Trials as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Several novel androgen receptor pathway targeted agents have recently entered on to therapeutic landscape for metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the effect of these novel androgen receptor pathway targeted agents in improving outcome of CRPC patients. Methods A literature-based meta-analysis of randomized controlled trials (RCTs) in accordance with the preferences for reported items in systematic reviews and meta-analyses guidelines was undertaken. Relevant publications from PubMed, the Cochrane Library, and abstracts from American Society of Clinical Oncology meetings were searched. The primary outcome was overall survival. The secondary end-points were time to the first symptomatic skeletal event, progression-free survival, prostatic antigen specific (PSA) response rate, time to PSA progression and safety. Results Pooled analysis from RCTs of novel androgen receptor pathway targeted agents revealed significantly increased overall survival compared with placebo or prednisone (hazard ratio [HR] for death: 0.79, 95% confidence interval [CI]: 0.71–0.87; P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2016.04.002